Prostate cancer decisions — 2024

The Veteran's erectile dysfunction, caused by service-connected prostate cancer residuals, qualifies for special monthly compensation based on loss of use of a creative organ.

The Board has denied the Veteran's claims for service connection for prostate cancer and skin cancer, finding that there is no evidence of herbicide exposure or a causal relationship to his military service.

The Veteran's prostate cancer, hypothyroidism, and diabetes mellitus, type II are presumed to be caused by exposure to herbicide agents during service.

The Veteran's type II diabetes mellitus and prostate cancer are granted on a presumptive basis due to herbicide exposure in Thailand.,The Veteran's renal failure is granted as secondary to his service-connected type II diabetes mellitus.,The Veteran's erectile dysfunction is denied as secondary to his service-connected prostate cancer. The claim was not submitted within the 90-day period following the Board hearing, and there was no duty-to-assist error related to this issue.

The Board has decided to remand the Veteran's claims for prostate cancer, erectile dysfunction, and prostatic hyperplasia due to potential service connection via another service-connected disability or toxic exposure risk activities (TERA). The claims will be reviewed again with new examinations and opinions.

The Board has decided to remand the case due to inadequate VA examination and the need for further exposure determination. The Veteran's prostate cancer claim is being reopened based on new evidence.

The Veteran withdrew his appeal for an increased rating for prostate cancer, and the Board has dismissed this claim.

The Board has determined that the reduction of the evaluation for prostate cancer from 100 percent to 20 percent, effective October 1, 2024, was procedurally proper. The Veteran's residuals of prostate cancer are currently rated as 20 percent disabling due to urinary incontinence and urinary frequency.

The Board has dismissed the appeal for payment or reimbursement of non-VA medical treatment on August 13, 2008 and has remanded the issue of entitlement to payment or reimbursement for prescriptions issued from November 2020 to January 2021.

The Board has remanded the case due to a lack of an etiological opinion and incomplete service treatment records. The Veteran's prostate cancer may be related to toxic exposure during active service, including Camp Lejeune.

The Veteran's prostate cancer and hypertension were rated, with a TDIU granted effective May 4, 2022. The prostate cancer was rated at 60 percent, the hypertension at noncompensable, and the TDIU was granted based on service-connected disabilities.

The Board has withdrawn the issues of service connection for the cause of the Veteran's death and DIC benefits under 38 U.S.C. § 1318, as well as a claim for DIC under 38 U.S.C. § 1151 due to VA treatment. The case is now remanded for further development.

The Veteran's claims for service connection are granted under the PACT Act, with some issues remanded.,Service connection is granted for HTN, DM, and prostate cancer as related to exposure to Agent Orange. Service connection is also granted for ED and urinary disability (urinary frequency) secondary to prostate cancer.

The Veteran's prostate cancer and coronary artery disease are granted on a presumptive basis under the PACT Act.,The Veteran's hypothyroidism is granted on a presumptive basis under the PACT Act. However, verification of service in Vietnam is needed to determine if an earlier effective date can be assigned.,The right knee disability is remanded for further development and medical opinion.

The Board has remanded the case due to inadequate medical opinion regarding service connection for prostate cancer status post radical proctectomy. The Veteran's lay statements and continuity of symptomatology since discharge from service are also considered.

The Board has decided to remand the claims for hypertension and prostate cancer residuals due to insufficient opinions regarding exposure to contaminants at Camp Lejeune.

The Veteran's prostate cancer is granted as service-connected due to presumed exposure to herbicide agents during his military service.

The Veteran's appeal for an increased rating for residuals of prostate cancer is remanded due to incomplete private treatment records from Keck Medicine. The Board will request these records and schedule the Veteran for a VA examination to determine the current severity of his service-connected condition.

The Veteran's cause of death is denied as the service-connected lung condition and prostate cancer are not found to have materially contributed to his death. Service connection for both conditions is also not established.

The Veteran's service connection claims for coronary artery disease, prostate cancer residuals, hypertension, and stroke/stroke residuals have been granted. The grants are based on presumptive exposure to herbicide agents during service.,Service connection has also been granted for carotid artery disease and erectile dysfunction, but the issues remain pending as they are related to other granted conditions.